Bayer scientists on Tuesday discussed a June draft report from regulators in four European Union countries that concluded the chemical meets the EU approval criteria for renewed registration. They also underscored the company's belief that the product offers benefits of effectiveness not available in its alternatives.
Balanced Reporting. Trusted Insights. Tuesday, September 21, 2021